BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah SC, Colombel J, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016;14:1245-1255.e8. [DOI: 10.1016/j.cgh.2016.01.015] [Cited by in Crossref: 132] [Cited by in F6Publishing: 122] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Day AS. Re: American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Transl Pediatr 2018;7:11-3. [PMID: 29441278 DOI: 10.21037/tp.2017.12.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Johnson CM, Linzay CD, Dassopoulos T. Maneuvering Clinical Pathways for Ulcerative Colitis. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0716-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 McNamee EN. Neutrophil-derived microRNAs put the (DNA) breaks on intestinal mucosal healing. J Clin Invest 2019;129:499-502. [PMID: 30640177 DOI: 10.1172/JCI125779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kjærgaard S, Damm MMB, Chang J, Riis LB, Rasmussen HB, Hytting-Andreasen R, Krug SM, Schulzke JD, Bindslev N, Hansen MB. Altered Structural Expression and Enzymatic Activity Parameters in Quiescent Ulcerative Colitis: Are These Potential Normalization Criteria? Int J Mol Sci 2020;21:E1887. [PMID: 32164249 DOI: 10.3390/ijms21051887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ponte A, Pinho R, Fernandes S, Rodrigues A, Alberto L, Silva JC, Silva J, Rodrigues J, Sousa M, Silva AP, Proença L, Freitas T, Leite S, Carvalho J. Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis. Inflamm Bowel Dis 2017;23:2238-44. [PMID: 28991857 DOI: 10.1097/MIB.0000000000001275] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
6 Omori T, Saruta M, Nagaki A, Arai Y, Ohta A, Kuramoto K, Suzuki Y. Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance. Expert Opin Pharmacother 2021;22:1505-11. [PMID: 33832402 DOI: 10.1080/14656566.2021.1905796] [Reference Citation Analysis]
7 Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:1298-308. [PMID: 34559428 DOI: 10.1111/apt.16605] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res 2021;19:419-29. [PMID: 33166442 DOI: 10.5217/ir.2020.00033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 144] [Cited by in F6Publishing: 124] [Article Influence: 28.8] [Reference Citation Analysis]
10 Ho SS, Wall C, Gearry RB, Keenan J, Day AS. A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease. Inflamm Intest Dis 2020;5:212-20. [PMID: 33313074 DOI: 10.1159/000510682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Limdi JK, Farraye FA. Automated endoscopic assessment in ulcerative colitis: the next frontier. Gastrointest Endosc 2021;93:737-9. [PMID: 33583524 DOI: 10.1016/j.gie.2020.10.032] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Furukawa S, Yagi S, Shiraishi K, Hashimoto Y, Kitahata S, Hanayama M, Tange K, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. The inverse association between unhealthy eating habit and mucosal healing among patients with ulcerative colitis. BMC Gastroenterol 2021;21:152. [PMID: 33827432 DOI: 10.1186/s12876-021-01724-6] [Reference Citation Analysis]
13 Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H, Morise T, Koyama Y, Uchida K, Suguro M, Matsumoto T, Yasuyuki K, Kawai T, Itoi T. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. PLoS One 2021;16:e0255620. [PMID: 34347848 DOI: 10.1371/journal.pone.0255620] [Reference Citation Analysis]
14 Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y, OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310-321. [PMID: 28593685 DOI: 10.1111/apt.14167] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 16.0] [Reference Citation Analysis]
15 Wen S, Zhong Z, He L, Zhao D, Chen X, Mi H, Liu F. Network pharmacology dissection of multiscale mechanisms for jiaoqi powder in treating ulcerative colitis. J Ethnopharmacol 2021;275:114109. [PMID: 33845143 DOI: 10.1016/j.jep.2021.114109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
17 Furukawa S, Yagi S, Shiraishi K, Mori K, Ninomiya T, Kawasaki K, Mizukami Y, Suzuki S, Uraoka M, Shibata N, Nakamura S, Imamine S, Murakami H, Ohashi K, Torisu M, Hasebe A, Yano H, Murakami M, Takeshita E, Ikeda Y, Hiasa Y. Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. BMC Gastroenterol 2020;20:384. [PMID: 33198664 DOI: 10.1186/s12876-020-01538-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chen JC. Research progress on regulation of intestinal mucosal barrier of patients with ulcerative colitis with traditional Chinese medicine. Shijie Huaren Xiaohua Zazhi 2020; 28(15): 725-729 [DOI: 10.11569/wcjd.v28.i15.725] [Reference Citation Analysis]
19 Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
20 Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64. [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113] [Cited by in Crossref: 313] [Cited by in F6Publishing: 263] [Article Influence: 104.3] [Reference Citation Analysis]
21 Iacucci M, Jeffery L, Acharjee A, Nardone OM, Zardo D, Smith SCL, Bazarova A, Cannatelli R, Shivaji UN, Williams J, Gkoutos G, Ghosh S. Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission. Inflamm Bowel Dis 2021:izab059. [PMID: 34019073 DOI: 10.1093/ibd/izab059] [Reference Citation Analysis]
22 Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467 [PMID: 29930467 DOI: 10.3748/wjg.v24.i23.2457] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
23 Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:1760-1768.e1. [PMID: 31546056 DOI: 10.1016/j.cgh.2019.09.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
24 Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S. 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. Curr Drug Targets 2021;22:117-25. [PMID: 32718289 DOI: 10.2174/1389450121666200727120305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Patel RN, Nigam GB, Jatale RG, Desai D, Makharia G, Ahuja V, Limdi JK. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol 2020;39:176-85. [PMID: 32483692 DOI: 10.1007/s12664-020-01047-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. J Gastroenterol Hepatol 2020;35:1893-901. [PMID: 32291796 DOI: 10.1111/jgh.15063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
28 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol 2018;9:136. [PMID: 29491393 DOI: 10.1038/s41424-018-0006-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
29 Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2021:izaa361. [PMID: 33501935 DOI: 10.1093/ibd/izaa361] [Reference Citation Analysis]
30 Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572-82. [PMID: 30174394 DOI: 10.20524/aog.2018.0276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
31 Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 115-46. [DOI: 10.1007/164_2016_122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
32 Shi HY, Chan FKL, Chan AWH, Higashimori A, Kyaw M, Ching JYL, Luk AKC, Wong SH, Wu JCY, Sung JJY, Ng SC. Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. Journal of Crohn's and Colitis 2017;11:1071-7. [DOI: 10.1093/ecco-jcc/jjx088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
33 Ricciuto A, Carman N, Benchimol EI, Siddiqui I, Putra J, Khanna R, Griffiths AM, Walters TD, Church PC. Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review. Am J Gastroenterol 2021. [PMID: 34388139 DOI: 10.14309/ajg.0000000000001400] [Reference Citation Analysis]
34 Lopez A, Pouillon L, Beaugerie L, Danese S, Peyrin-Biroulet L. Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol 2018;32-33:103-9. [PMID: 30060933 DOI: 10.1016/j.bpg.2018.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
35 Takano R, Osawa S, Uotani T, Tani S, Ishida N, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Miyajima H, Sugimoto K. Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission. World J Clin Cases 2018; 6(15): 952-960 [PMID: 30568951 DOI: 10.12998/wjcc.v6.i15.952] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
36 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Duijvestein M, Battat R, Vande Casteele N, D’haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastro 2018;16:129-46. [DOI: 10.1007/s11938-018-0175-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
39 Kornbluth A. Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right? Inflamm Bowel Dis 2020;26:1730-2. [PMID: 32031216 DOI: 10.1093/ibd/izz333] [Reference Citation Analysis]
40 Lee SH, Kim MJ, Chang K, Song EM, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol 2017;17:110. [PMID: 29061121 DOI: 10.1186/s12876-017-0669-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
41 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Reference Citation Analysis]
42 Jairath V, Mcdonald JW, Feagan BG. Ulcerative Colitis. In: Feagan BG, Kahrilas PJ, Jalan R, Mcdonald JWD, editors. Evidence-based Gastroenterology and Hepatology 4e. Chichester: John Wiley & Sons, Ltd; 2019. pp. 173-86. [DOI: 10.1002/9781119211419.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Dig Liver Dis 2020;52:704-20. [PMID: 32402743 DOI: 10.1016/j.dld.2020.03.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol 2019;114:733-45. [DOI: 10.14309/ajg.0000000000000111] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
45 Narula N, Kassam Z, Yuan Y, Colombel JF, Ponsioen C, Reinisch W, Moayyedi P. Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis. 2017;23:1702-1709. [PMID: 28906291 DOI: 10.1097/mib.0000000000001228] [Cited by in Crossref: 95] [Cited by in F6Publishing: 41] [Article Influence: 23.8] [Reference Citation Analysis]
46 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
47 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Reference Citation Analysis]
48 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
49 Bergenheim F, Seidelin JB, Pedersen MT, Mead BE, Jensen KB, Karp JM, Nielsen OH. Fluorescence-based tracing of transplanted intestinal epithelial cells using confocal laser endomicroscopy. Stem Cell Res Ther 2019;10:148. [PMID: 31133056 DOI: 10.1186/s13287-019-1246-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
50 Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol 2021;15:665-74. [PMID: 33481635 DOI: 10.1080/17474124.2021.1880892] [Reference Citation Analysis]
51 Moses J, Sandberg K, Winberry G, Riera D, DeLozier S, Gupta SK, Reilly N, Park KT, Picoraro J. Clinical Practice Survey of Repeat Endoscopy in Pediatric Inflammatory Bowel Disease in North America. J Pediatr Gastroenterol Nutr 2021;73:61-6. [PMID: 33633082 DOI: 10.1097/MPG.0000000000003100] [Reference Citation Analysis]
52 Jerger L, Hyams JS. Special considerations for biologic medications in pediatric ulcerative colitis. Expert Opin Biol Ther 2020;20:429-35. [PMID: 31652087 DOI: 10.1080/14712598.2020.1685492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Moussa L, Lapière A, Squiban C, Demarquay C, Milliat F, Mathieu N. BMP Antagonists Secreted by Mesenchymal Stromal Cells Improve Colonic Organoid Formation: Application for the Treatment of Radiation-induced Injury. Cell Transplant 2020;29:963689720929683. [PMID: 33108903 DOI: 10.1177/0963689720929683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 Spergel JM, Aceves SS, Greenhawt M. Challenges with the technical review of eosinophilic esophagitis: discussion points for the practicing allergist. Ann Allergy Asthma Immunol 2020;124:411-3. [PMID: 32336460 DOI: 10.1016/j.anai.2020.03.011] [Reference Citation Analysis]
56 Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372-84. [PMID: 34090625 DOI: 10.1016/S0140-6736(21)00666-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Park J, Kang SJ, Yoon H, Park J, Oh HJ, Na HY, Lee HS, Shin CM, Park YS, Kim N, Lee DH. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse. Inflamm Bowel Dis 2022:izab340. [PMID: 35016209 DOI: 10.1093/ibd/izab340] [Reference Citation Analysis]
58 Tan Y, Guan Y, Sun Y, Zheng C. Correlation of Intestinal Mucosal Healing and Tight Junction Protein Expression in Ulcerative Colitis Patients. Am J Med Sci. 2019;357:195-204. [PMID: 30638599 DOI: 10.1016/j.amjms.2018.11.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
59 Saiz ML, Cibrian D, Ramírez-Huesca M, Torralba D, Moreno-Gonzalo O, Sánchez-Madrid F. Tetraspanin CD9 Limits Mucosal Healing in Experimental Colitis. Front Immunol 2017;8:1854. [PMID: 29312336 DOI: 10.3389/fimmu.2017.01854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
60 Watanabe J, Furukawa S, Yagi S, Shiraishi K, Hanayama M, Tange K, Hashimoto Y, Kitahata S, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Ikeda Y, Hiasa Y. Time spent per day in strenuous activity and total physical activity are inversely associated with mucosal healing but not with clinical remission in patients with ulcerative colitis. Ann Gastroenterol 2021;34:796-801. [PMID: 34815645 DOI: 10.20524/aog.2021.0663] [Reference Citation Analysis]
61 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
62 Sexton KA, Walker JR, Graff LA, Bernstein MT, Beatie B, Miller N, Sargent M, Targownik LE. Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017;23:473-83. [DOI: 10.1097/mib.0000000000001040] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 6.6] [Reference Citation Analysis]
63 O'connell L, Winter DC. Organoids: Past Learning and Future Directions. Stem Cells and Development 2020;29:281-9. [DOI: 10.1089/scd.2019.0227] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
64 Bislenghi G, Ferrante M, Sabino J, Verstockt B, Martin-perez B, Fieuws S, Wolthuis A, Vermeire S, D’hoore A. Short- and Long-term Outcomes Following Side-to-side Strictureplasty and its Modification Over the Ileocaecal Valve for Extensive Crohn’s Ileitis. Journal of Crohn's and Colitis 2020;14:1378-84. [DOI: 10.1093/ecco-jcc/jjaa066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Gong L, Zhang YL, Sun LX, Chen GR, Wu D. Mucosal healing in intestinal Behçet's disease: A systematic review and meta-analysis. J Dig Dis 2021;22:83-90. [PMID: 33314672 DOI: 10.1111/1751-2980.12965] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis 2021;53:980-6. [PMID: 33640302 DOI: 10.1016/j.dld.2021.02.006] [Reference Citation Analysis]
67 Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50:40-53. [PMID: 31165509 DOI: 10.1111/apt.15294] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
68 Conklin LS, Hanley PJ, Galipeau J, Barrett J, Bollard CM. Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience. Cytotherapy 2017;19:655-67. [PMID: 28433516 DOI: 10.1016/j.jcyt.2017.03.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
69 Narula N, Alshahrani A, Yuan Y, Reinisch W, Colombel J. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2019;17:411-418.e3. [DOI: 10.1016/j.cgh.2018.06.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
70 Holmberg FE, Seidelin JB, Yin X, Mead BE, Tong Z, Li Y, Karp JM, Nielsen OH. Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. EMBO Mol Med. 2017;9:558-570. [PMID: 28283650 DOI: 10.15252/emmm.201607260] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
71 Sébert M, Denadai-Souza A, Quaranta M, Racaud-Sultan C, Chabot S, Lluel P, Monjotin N, Alric L, Portier G, Kirzin S, Bonnet D, Ferrand A, Vergnolle N. Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism. Br J Pharmacol 2018;175:3656-68. [PMID: 29959891 DOI: 10.1111/bph.14430] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
72 Romera-Hernández M, Aparicio-Domingo P, Papazian N, Karrich JJ, Cornelissen F, Hoogenboezem RM, Samsom JN, Cupedo T. Yap1-Driven Intestinal Repair Is Controlled by Group 3 Innate Lymphoid Cells. Cell Rep 2020;30:37-45.e3. [PMID: 31914395 DOI: 10.1016/j.celrep.2019.11.115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
73 Dolan KT, Chang EB. Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Mol Nutr Food Res 2017;61. [PMID: 27346644 DOI: 10.1002/mnfr.201600129] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
74 Moran CP, Neary B, Doherty GA. Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc 2016; 8(20): 723-732 [PMID: 28042386 DOI: 10.4253/wjge.v8.i20.723] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
75 Mennillo E, Yang X, Paszek M, Auwerx J, Benner C, Chen S. NCoR1 Protects Mice From Dextran Sodium Sulfate-Induced Colitis by Guarding Colonic Crypt Cells From Luminal Insult. Cell Mol Gastroenterol Hepatol 2020;10:133-47. [PMID: 32044398 DOI: 10.1016/j.jcmgh.2020.01.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Lazzerini M, Villanacci V, Pellegrin MC, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Fontana M, Zuin G, Maggiore G, Bramuzzo M, Maschio M, Salemme M, Manenti S, Lorenzi L, Decorti G, Montico M, Ventura A. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol 2017;15:1382-1389.e1. [PMID: 28286192 DOI: 10.1016/j.cgh.2017.02.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
77 Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
78 Motobayashi M, Matsuoka K, Takenaka K, Fujii T, Nagahori M, Ohtsuka K, Iwamoto F, Tsuchiya K, Negi M, Eishi Y, Watanabe M. Predictors of mucosal healing during induction therapy in patients with acute moderate‐to‐severe ulcerative colitis. Journal of Gastroenterology and Hepatology 2018;34:1004-10. [DOI: 10.1111/jgh.14565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
80 Li J, Leung WK. Colon capsule endoscopy for inflammatory bowel disease: Colon capsule endoscopy for IBD. Journal of Digestive Diseases 2018;19:386-94. [DOI: 10.1111/1751-2980.12614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
81 Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Takada T, Kinoshita K, Allocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:908-921.e6. [PMID: 32777549 DOI: 10.1016/j.cgh.2020.07.067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
82 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
83 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
84 Hoekman DR, Diederen K, Koot BG, Tabbers MM, Kindermann A, Benninga MA. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr 2016;175:1335-42. [PMID: 27573259 DOI: 10.1007/s00431-016-2762-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
85 Simian D, Fluxá D, Flores L, Lubascher J, Ibáñez P, Figueroa C, Kronberg U, Acuña R, Moreno M, Quera R. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol 2016; 22(22): 5267-5275 [PMID: 27298570 DOI: 10.3748/wjg.v22.i22.5267] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
86 Sousa HT, Brito J, Magro F. New cross-sectional imaging in IBD. Curr Opin Gastroenterol 2018;34:194-207. [PMID: 29846256 DOI: 10.1097/MOG.0000000000000440] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
87 Pugliese D, Aratari A, Festa S, Ferraro PM, Monterubbianesi R, Guidi L, Scribano ML, Papi C, Armuzzi A. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterol Res Pract 2018;2018:4195968. [PMID: 30402090 DOI: 10.1155/2018/4195968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Shi HY, Chan FKL, Higashimori A, Kyaw M, Ching JYL, Chan HCH, Chan JCH, Chan AWH, Lam KLY, Tang RSY. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointest Endosc. 2017;86:1139-1146.e6. [PMID: 28713062 DOI: 10.1016/j.gie.2017.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
89 Frieri G, Galletti B, Di Ruscio M, Tittoni R, Capannolo A, Serva D, Latella G, Sollima L, Leocata P, Necozione S, Frieri R, Viscido A. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. Therap Adv Gastroenterol 2017;10:749-59. [PMID: 29051786 DOI: 10.1177/1756283X17722926] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
90 Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24(33): 3681-3694 [PMID: 30197475 DOI: 10.3748/wjg.v24.i33.3681] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 54] [Article Influence: 17.8] [Reference Citation Analysis]
91 Ashrafizadeh M, Najafi M, Mohammadinejad R, Farkhondeh T, Samarghandian S. Berberine Administration in Treatment of Colitis: A Review. Curr Drug Targets 2020;21:1385-93. [PMID: 32564751 DOI: 10.2174/1389450121666200621193758] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
93 Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol 2016; 22(42): 9324-9332 [PMID: 27895420 DOI: 10.3748/wjg.v22.i42.9324] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
94 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
95 Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi DS, Lukas M, Bortlik M, Wu K, Sood A, Schwartz DA, Sandborn WJ;  Global Interventional Inflammatory Bowel Disease Group. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc. 2019;89:215-237. [PMID: 30365985 DOI: 10.1016/j.gie.2018.09.045] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
96 Popa DE, Manea NC, Gheonea DI, PÎrlog MC. Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease. Curr Health Sci J 2020;46:103-10. [PMID: 32874680 DOI: 10.12865/CHSJ.46.02.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
98 Adler SN, González Lama Y, Matallana Royo V, Suárez Ferrer C, Schwartz A, Bar-Gil Shitrit A. Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity. Endosc Int Open 2019;7:E1253-61. [PMID: 31579707 DOI: 10.1055/a-0982-2786] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
99 Furukawa S, Ikeda Y, Yagi S, Miyake T, Shiraishi K, Tange K, Hashimoto Y, Mori K, Ninomiya T, Suzuki S, Shibata N, Murakami H, Ohashi K, Hasebe A, Tomida H, Yamamoto Y, Takeshita E, Hiasa Y. Association Between Peripheral Blood Monocyte Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis. Clin Transl Gastroenterol 2021;12:e00429. [PMID: 34797817 DOI: 10.14309/ctg.0000000000000429] [Reference Citation Analysis]
100 Holmberg FE, Pedersen J, Jørgensen P, Soendergaard C, Jensen KB, Nielsen OH. Intestinal barrier integrity and inflammatory bowel disease: Stem cell‐based approaches to regenerate the barrier. J Tissue Eng Regen Med 2018;12:923-35. [DOI: 10.1002/term.2506] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
101 Honig G, Heller C, Hurtado-Lorenzo A. Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2020;26:1451-62. [PMID: 32812036 DOI: 10.1093/ibd/izaa210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
102 Kayal M, Plietz M, Radcliffe M, Rizvi A, Yzet C, Tixier E, Hirten RP, Cohen B, Sylla P, Khaitov S, Greenstein A, Colombel JF, Dubinsky MC, Ungaro RC. Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. Aliment Pharmacol Ther 2019;50:1189-94. [PMID: 31579976 DOI: 10.1111/apt.15505] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
103 Balderramo D, Trakal J, Herrera Najum P, Vivas M, Gonzalez R, Benavidez A, López Villa D, Daino D, Raiden K, Germán A, Corzo MA, Ponce de León J, Ferrer L, Germán C, Bálzola S, Idoeta A, Zárate F, Defagó MR. High ulcerative colitis and Crohn's disease ratio in a population-based registry from Córdoba, Argentina. Digestive and Liver Disease 2021;53:852-7. [DOI: 10.1016/j.dld.2021.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Al Khoury A, Balram B, Bessissow T, Afif W, Gonczi L, Abreu M, Lakatos PL. Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review. Dig Dis Sci 2021. [PMID: 34021425 DOI: 10.1007/s10620-021-07025-y] [Reference Citation Analysis]
105 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Aden K, Breuer A, Rehman A, Geese H, Tran F, Sommer J, Waetzig GH, Reinheimer TM, Schreiber S, Rose-John S, Scheller J, Rosenstiel P. Classic IL-6R signalling is dispensable for intestinal epithelial proliferation and repair. Oncogenesis 2016;5:e270. [PMID: 27869785 DOI: 10.1038/oncsis.2016.71] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
107 Sakuraba A, Nemoto N, Hibi N, Ozaki R, Tokunaga S, Kikuchi O, Minowa S, Mitsui T, Miura M, Saito D, Hayashida M, Miyoshi J, Matsuura M, Yoneyama M, Ohnishi H, Hisamatsu T. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol 2021;21:197. [PMID: 33933033 DOI: 10.1186/s12876-021-01788-4] [Reference Citation Analysis]
108 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Scarallo L, Bolasco G, Barp J, Bianconi M, di Paola M, Di Toma M, Naldini S, Paci M, Renzo S, Labriola F, De Masi S, Alvisi P, Lionetti P. Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis 2021:izab046. [PMID: 33835155 DOI: 10.1093/ibd/izab046] [Reference Citation Analysis]
110 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
111 Im JP, Ye BD, Kim YS, Kim JS. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med 2018;33:28-35. [PMID: 29334728 DOI: 10.3904/kjim.2017.400] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
112 Du G, Xiong L, Li X, Zhuo Z, Zhuang X, Yu Z, Wu L, Xiao D, Liu Z, Jie M, Liu X, Luo G, Guo Z, Chen H. Peroxisome Elevation Induces Stem Cell Differentiation and Intestinal Epithelial Repair. Dev Cell 2020;53:169-184.e11. [PMID: 32243783 DOI: 10.1016/j.devcel.2020.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
113 White JR, Jairath V, Moran GW. Evolution of treatment targets in Crohn's disease. Best Pract Res Clin Gastroenterol 2019;38-39:101599. [PMID: 31327410 DOI: 10.1016/j.bpg.2019.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Osterman MT, Scott FI, Fogt FF, Gilroy ED, Parrott S, Galanko J, Cross R, Moss A, Herfarth HH, Higgins PDR. Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). Inflamm Bowel Dis 2021;27:207-14. [PMID: 32170946 DOI: 10.1093/ibd/izaa048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
115 Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019;14:e0212989. [PMID: 30807613 DOI: 10.1371/journal.pone.0212989] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
116 Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M. Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 2017;52:1031-40. [PMID: 28321512 DOI: 10.1007/s00535-017-1325-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
117 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
118 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
119 Narula N, Wong ECL, Colombel JF, Riddell R, Marshall JK, Reinisch W, Dulai PS. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00716-3. [PMID: 34229037 DOI: 10.1016/j.cgh.2021.07.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. J Crohns Colitis. 2017;11:53-59. [PMID: 27402915 DOI: 10.1093/ecco-jcc/jjw122] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
121 Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00820-X. [PMID: 34329776 DOI: 10.1016/j.cgh.2021.07.038] [Reference Citation Analysis]
122 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
123 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
124 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
125 Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY. Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:858-65. [PMID: 28509817 DOI: 10.1097/MIB.0000000000001152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
126 Shiraishi K, Furukawa S, Yagi S, Hanayama M, Mori K, Ninomiya T, Suzuki S, Ohashi K, Murakami H, Takeshita E, Ikeda Y, Hiasa Y. Association between serum bilirubin and mucosal healing among Japanese patients with ulcerative colitis: a cross-sectional study. Int J Colorectal Dis 2021;36:377-82. [PMID: 33040190 DOI: 10.1007/s00384-020-03774-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Ho SSC, Keenan JI, Day AS. Parent Perspectives of Diagnostic and Monitoring Tests Undertaken by Their Child with Inflammatory Bowel Disease. Pediatr Gastroenterol Hepatol Nutr 2021;24:19-29. [PMID: 33505890 DOI: 10.5223/pghn.2021.24.1.19] [Reference Citation Analysis]
128 Monstad IL, Solberg IC, Cvancarova M, Hovde O, Henriksen M, Huppertz-Hauss G, Gunther E, Moum BA, Stray N, Vatn M, Hoie O, Jahnsen J. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis 2021;15:969-79. [PMID: 33367569 DOI: 10.1093/ecco-jcc/jjaa232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
129 Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T. Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intest Res 2018;16:168-77. [PMID: 29743830 DOI: 10.5217/ir.2018.16.2.168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
130 Shiraishi K, Furukawa S, Yagi S, Mori K, Ninomiya T, Kawasaki K, Mizukami Y, Suzuki S, Uraoka M, Shibata N, Nakamura S, Imamine S, Murakami H, Ohashi K, Torisu M, Yano M, Hasebe A, Yano H, Murakami M, Takeshita E, Ikeda Y, Hiasa Y. Serum Globulin Is Associated with Endoscopic Findings and Mucosal Healing in Japanese Patients with Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 33537920 DOI: 10.1007/s10620-021-06834-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Heier CR, Fiorillo AA, Chaisson E, Gordish-Dressman H, Hathout Y, Damsker JM, Hoffman EP, Conklin LS. Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. Clin Transl Gastroenterol 2016;7:e192. [PMID: 27628422 DOI: 10.1038/ctg.2016.49] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
132 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
133 Niv Y. Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn’s disease: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology 2017;29:844-8. [DOI: 10.1097/meg.0000000000000881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
134 Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JWD, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA, Boland BS, Singh S, Dulai PS, Valasek MA, Feagan BG, Jairath V, Sandborn WJ. Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther 2020;52:1574-82. [PMID: 32981088 DOI: 10.1111/apt.16083] [Reference Citation Analysis]